BIOVENTUS INC. (BVS) FY2026 Q2 P&L / Income Statement

BIOVENTUS INC. (BVS) FY2026 Q2 P&L / Income Statement

Income statement for 2026-03-29 through 2026-06-27. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Net sales

153,208,000 US dollars

Cost of sales (including depreciation and amortization of $9,893, $10,603, $19,980 and $20,868, respectively)

47,542,000 US dollars

Gross profit

105,666,000 US dollars

Operating costs, net of other operating income (calculated)

86,539,000 US dollars

Operating income

19,127,000 US dollars

Other expense

negative 3,819,000 US dollars

Income before income taxes

15,308,000 US dollars

Income tax (benefit) expense, net

negative 20,897,000 US dollars

Net income

36,205,000 US dollars

Pain Treatments - UNITED STATES

72,704,000 US dollars

Pain Treatments - International

9,044,000 US dollars

Restorative Therapies - UNITED STATES

18,176,000 US dollars

Restorative Therapies - International

2,932,000 US dollars

Surgical Solutions - UNITED STATES

43,585,000 US dollars

Surgical Solutions - International

6,767,000 US dollars

Selling, general and administrative expense

82,740,000 US dollars

Research and development expense

3,173,000 US dollars

Restructuring costs

negative 415,000 US dollars

Depreciation and amortization

1,041,000 US dollars

Loss on disposals

0 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
• Of which attributable to BIOVENTUS INC.: $33.44 M; to noncontrolling interests: $2.76 M.